跳到主要內容

臺灣博碩士論文加值系統

(18.204.48.64) 您好!臺灣時間:2021/08/03 12:48
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:戴儒君
研究生(外文):Ju-Chan Tai
論文名稱:建立癌症治療標靶細胞株
論文名稱(外文):Establishment of the targeted cell line for anticancer therapy
指導教授:尤文正
指導教授(外文):Wen-Jen Yu
學位類別:碩士
校院名稱:弘光科技大學
系所名稱:生物科技研究所
學門:生命科學學門
學類:生物科技學類
論文種類:學術論文
畢業學年度:100
語文別:中文
論文頁數:122
中文關鍵詞:體抑素體抑素受體綠色螢光基因綠色螢光基因微脂體阿黴素標靶藥物
外文關鍵詞:SomatostatinSomatostatin receptorGreen fluorescent proteinLuciferase geneLiposome DoxorubicinTargeted drug
相關次數:
  • 被引用被引用:0
  • 點閱點閱:236
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:1
體抑素受體 (Somatostatin receptors, SSTRs) 亦稱為生長抑制素受體,可調節多種內、外分泌作用,目前已知五種亞型 (SSTR1-5),屬於七個跨膜 G 蛋白偶聯受體,主要存在於腦、胰腺、胃和腎臟等組織,但在腫瘤組織的分佈及表現量則迥異。體抑素及其同類化合物 (analogue) 可以藉由與 SSTRs 的作用抑制神經內分泌胃腸胰臟腫瘤 (Neuroendocrine gastroenteropancreatic tumor) 的生長,因此,SSTRs 的調控機制適合開發標靶治療策略。然而,由腫瘤組織所分離培養的癌細胞株卻大多無法過量表達 SSTRs,因此,以一般的癌細胞株並不適合評估 SSTR 路徑標靶治療的效果。
有鑑於此,本論文先以基因工程技術建構具有 SSTR、EGFP、Luciferase 報導基因及 Puromycin 抗藥性基因的質體 (SLPE2),利用限制酶 (restriction enzyme) 確認質體正確性,再以轉染方式將 SLPE2 質體攜至不同細胞株;轉殖基因之功能則以反轉錄聚合酶連鎖反應 (RT-PCR)、西方墨點 (Western blot)、綠色螢光 (EGFP) 及冷光 (Luciferase) 表現、抗藥性 (Puromycin) 試驗等方法證實。過量表達 SSTR 之穩定細胞株,再利用流式細胞儀 (FACS) 、細胞毒性 (MTT) 分析法評估穩定表達 SSTR 的細胞株 (MCF7-2G2) 與標靶藥物親和力及毒性作用。同時,以 1 x 106 細胞數注射 SSTR 細胞株 (AR42J-2G2) 於裸鼠右後肢處建立腫瘤動物模式。
結果顯示,SLPE2 質體經限制酶 (restriction enzyme) 剪切及定序,確認質體序列正確性。轉染質體細胞株生長及形態並未受到影響;免疫螢光染色、抗藥性 (Puromycin)、反轉錄聚合酶連鎖反應、西方墨點分析證實,成功建立數種穩定表達 SSTR 之細胞株。標靶藥物 (SST-Lipo-Dox) 對穩定表達 SSTR 細胞株的親和力較傳統藥物 (Lipo-Doxorubicin, Lipo-Dox) 佳。動物實驗結果也證實,標靶藥物可抑制腫瘤增生,其劑量(0.66 mg/kg) 較傳統藥物 (3.33 mg/kg) 低五倍,副作用也較輕微。
本論文已成功建立穩定表現過量 SSTR 的細胞株 (T47D, AR42J, MCF7),並具有 EGFP、Luciferase 兩種報導基因,可作為篩選 SSTR 途徑抗癌藥物的細胞平台。同時,動物實驗結果也顯示,穩定過量表現 SSTR 的細胞株 (AR42J-2G2) 可建立腫瘤小鼠模式,未來亦可應用此動物模式做為篩選 SSTR 途徑標靶藥物的動物平台。

Somatostatin receptors (SSTRs) are known as growth inhibitory receptors and reported to regulate various exocrine and endocrine homeostasis. Five SSTR subtypes (SSTR1–5) were documented and classified as the family of G-protein coupled receptors which possess seven transmembrane domains. The expression profiles of endogenous SSTRs are mainly in brain, pancreas, stomach and kidney tissues which differ from those in tumor tissues. Somatostatin and its analogue were found to inhibit the neuroendocrine gastroenteropancreatic tumor growth. Therefore, it is possible to develop the strategy for targeting therapy via SSTRs pathways. However, absence or few SSTRs expression were found in the cancer cell lines which derived from tumor tissues with aboundant SSTRs expresion. It is not appropriate to use the commencial tumor cell lines for the evaluation of targeting therapy via SSTRs pathway.
In this study, we co-constructed the plasmid with SSTR cDNA, EGFP and luciferase reporter genes, and puromycin resistant genes (SLPE2) for the establishment of SSTR stable cell lines. The objective of this study was to generate the stable cell lines which over-express SSTR and suitable for the platforms for targeting therapy in vitro or in vivo. The SLPE2 plasmid was confirmed by restriction map and transfected into various cell lines. Cells carried the SLPE2 plasmid were enriched by antibiotics selection and approved by reporter gene and SSTR gene expression using RT-PCR and Western blotting. The affinity to targeting drug and cytotoxicity of selected SSTR all lines were further examined by fluorescence activated cell sorting (FACS) and MTT, respectively. In addition, the animal tumor model was generated by injecting 1x106 SSTR cells into the right hind legs of nude mice.
Three stable SSTR cell lines (T47D, AR42J, MCF7) with normal growth rate and cell morphology were successfully established for the subsequent experiments. The results of cell and animal experiments indicated that the targeting drug (SST-Lipo-Dox) caused an adverse effects on the SSTR tumor cell growth and reduced the side effects of tumor therapy in invo.
In the presents study, we successfully generated three stable SSTRs cell lines (T47D, AR42J, MCF7) with dual reporter genes (EGFP, luciferase) that can be used as in vitro and in invo platforms for the targeted anti-cancer drug screening through the SSTR pathway.

圖目錄............................................IV
表目錄............................................VI
附圖目錄.........................................VII
縮寫表..........................................VIII
致謝..............................................X
中文摘要..........................................XI
英文摘要........................................XIII
第一章 前言 ......................................1
研究動機與目的 ...................................3
第二章 文獻探討 ...................................4
1. 國人十大死因...................................4
2. 癌症的介紹 ...................................5
3. 微脂體 (Liposome) 簡介........................11
4. 阿黴素簡介....................................15
5. 體抑素簡介 (Somatostatin, SST)................18
第三章 材料與方法..................................26
Ⅰ.實驗藥品.......................................26
Ⅱ.實驗儀器.......................................32
Ⅲ.常用溶液配置...................................33
Ⅳ.實驗架構......................................38
Ⅴ.實驗方法.......................................39
1.SSTR 抗藥基因之建立.............................39
2.抗藥性癌細胞株之建立.............................46
3. RNA 萃取.................................... 50
4.去除 DNA......................................51
5.反轉錄作用 (Reverse Transcription).............51
6.聚合酶連鎖反應 (Polymerase chain reaction)......51
7.西方墨點法.....................................52
8.實驗動物.......................................54
第四章 結果.......................................57
1. 重組質體之構築.................................57
2. 質體功能性試驗.................................60
3. 腫瘤動物模式之抗藥性試驗.........................65
第五章 討論.......................................67
結論............................................72
第六章 參考文獻....................................73


Aggarwal, C., and C.J. Langer. 2012. Older age, poor performance status and major comorbidities: how to treat high-risk patients with advanced nonsmall cell lung cancer. Curr Opin Oncol. 24:130-136.
Alberts, S.R., D.J. Sargent, S. Nair, M.R. Mahoney, M. Mooney, S.N. Thibodeau, T.C. Smyrk, F.A. Sinicrope, E. Chan, S. Gill, M.S. Kahlenberg, A.F. Shields, J.T. Quesenberry, T.A. Webb, G.H. Farr, Jr., B.A. Pockaj, A. Grothey, and R.M. Goldberg. 2012. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 307:1383-1393.
Albini, A., T. Florio, D. Giunciuglio, L. Masiello, S. Carlone, A. Corsaro, S. Thellung, T. Cai, D.M. Noonan, and G. Schettini. 1999. Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. FASEB J. 13:647-655.
Barasch, A., and J.B. Epstein. 2011. Management of cancer therapy-induced oral mucositis. Dermatol Ther. 24:424-431.
Baselga, J., D. Tripathy, J. Mendelsohn, S. Baughman, C.C. Benz, L. Dantis, N.T. Sklarin, A.D. Seidman, C.A. Hudis, J. Moore, P.P. Rosen, T. Twaddell, I.C. Henderson, and L. Norton. 1996. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 14:737-744.
Bauer, W., U. Briner, W. Doepfner, R. Haller, R. Huguenin, P. Marbach, T.J. Petcher, and Pless. 1982. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 31:1133-1140.
Beal, M.F., R.A. Clevens, and M.F. Mazurek. 1988. Somatostatin and neuropeptide Y immunoreactivity in Parkinson's disease dementia with Alzheimer's changes. Synapse. 2:463-467.
Berruti, A., L. Dogliotti, A. Mosca, R. Tarabuzzi, M. Torta, M. Mari, G. Gorzegno, D. Fontana, and A. Angeli. 2001. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients. Prostate. 47:205-211.
Biswas, S., N.S. Dodwadkar, P.P. Deshpande, and V.P. Torchilin. 2012. Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. J Control Release.
Boucek, M.M., R.J. Novick, L.E. Bennett, B. Fiol, B.M. Keck, and J.D. Hosenpud. 1997. The Registry of the International Society of Heart and Lung Transplantation: first official pediatric report-1997. J Heart Lung Transplant. 16:1189-1206.
Bousquet, C., E. Puente, L. Buscail, N. Vaysse, and C. Susini. 2001. Antiproliferative effect of somatostatin and analogs. Chemotherapy. 47 Suppl 2:30-39.
Brazeau, P., W. Vale, R. Burgus, N. Ling, M. Butcher, J. Rivier, and R. Guillemin. 1973. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 179:77-79.
Burghardt, B., K. Barabas, Z. Marcsek, L. Flautner, T.M. Gress, and G. Varga. 2000. Inhibitory effect of a long-acting somatostatin analogue on EGF-stimulated cell proliferation in Capan-2 cells. J Physiol Paris. 94:57-62.
Buscail, L., N. Delesque, J.P. Esteve, N. Saint-Laurent, H. Prats, P. Clerc, P. Robberecht, G.I. Bell, C. Liebow, A.V. Schally, and et al. 1994. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci U S A. 91:2315-2319.
Campone, M., D. Berton-Rigaud, E. Bourbouloux, S. Sophie, A. Zanetti, and J.S. Frenel. 2011. [Her2 positive breast cancer: practices]. Bull Cancer. 98:154-163.
Caroni, P., F. Villani, and E. Carafoli. 1981. The cardiotoxic antibiotic doxorubicin inhibits the Na+/Ca2+ exchange of dog heart sarcolemmal vesicles. FEBS Lett. 130:184-186.
Cashin, P.H., W. Graf, P. Nygren, and H. Mahteme. 2012. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: Prognosis and treatment of recurrences in a cohort study. Eur J Surg Oncol.
Chalfie, M., Y. Tu, G. Euskirchen, W.W. Ward, and D.C. Prasher. 1994. Green fluorescent protein as a marker for gene expression. Science. 263:802-805.
Chang, R., S. Nir, and F.R. Poulain. 1998. Analysis of binding and membrane destabilization of phospholipid membranes by surfactant apoprotein B. Biochim Biophys Acta. 1371:254-264.
Chon, S.Y., R.W. Champion, E.R. Geddes, and R.M. Rashid. 2011. Chemotherapy-induced alopecia. J Am Acad Dermatol.
Chowers, Y., L. Cahalon, M. Lahav, H. Schor, R. Tal, S. Bar-Meir, and M. Levite. 2000. Somatostatin through its specific receptor inhibits spontaneous and TNF-alpha- and bacteria-induced IL-8 and IL-1 beta secretion from intestinal epithelial cells. J Immunol. 165:2955-2961.
Cianchetti, M., M.A. Varvares, D.G. Deschler, N.J. Liebsch, J.J. Wang, and A.W. Chan. 2012. Risk of sinonasal-cutaneous fistula after treatment for advanced sinonasal cancer. J Surg Oncol. 105:261-265.
Cobleigh, M.A., C.L. Vogel, D. Tripathy, N.J. Robert, S. Scholl, L. Fehrenbacher, J.M. Wolter, V. Paton, S. Shak, G. Lieberman, and D.J. Slamon. 1999. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 17:2639-2648.
Corleto, V.D., S. Nasoni, F. Panzuto, S. Cassetta, and G. Delle Fave. 2004. Somatostatin receptor subtypes: basic pharmacology and tissue distribution. Dig Liver Dis. 36 Suppl 1:S8-16.
Cort, A., M. Timur, E. Ozdemir, E. Kucuksayan, and T. Ozben. 2012. Synergistic anticancer activity of curcumin and bleomycin: An in vitro study using human malignant testicular germ cells. Mol Med Report.
Cullis, P.R., A. Chonn, and S.C. Semple. 1998. Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo. Adv Drug Deliv Rev. 32:3-17.
Cunningham, D., Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A. Harstrick, C. Verslype, I. Chau, and E. Van Cutsem. 2004. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 351:337-345.
Czuczman, M.S., A. Koryzna, A. Mohr, C. Stewart, K. Donohue, L. Blumenson, Z.P. Bernstein, P. McCarthy, A. Alam, F. Hernandez-Ilizaliturri, M. Skipper, K. Brown, A. Chanan-Khan, D. Klippenstein, P. Loud, M.K. Rock, M. Benyunes, A. Grillo-Lopez, and S.H. Bernstein. 2005. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol. 23:694-704.
Dasgupta, P. 2004. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther. 102:61-85.
Davies, N., J. Yates, H. Kynaston, B.A. Taylor, and S.A. Jenkins. 1997. Effects of octreotide on liver regeneration and tumour growth in the regenerating liver. J Gastroenterol Hepatol. 12:47-53.
Day, R., W. Dong, R. Panetta, J. Kraicer, M.T. Greenwood, and Y.C. Patel. 1995. Expression of mRNA for somatostatin receptor (sstr) types 2 and 5 in individual rat pituitary cells. A double labeling in situ hybridization analysis. Endocrinology. 136:5232-5235.
De Beer, E.L., A.E. Bottone, and E.E. Voest. 2001. Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review. Eur J Pharmacol. 415:1-11.
De Luca, A., M.R. Maiello, A. D'Alessio, M. Pergameno, and N. Normanno. 2012. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 16:S17-S27.
Duran-Prado, M., M.D. Gahete, M. Hergueta-Redondo, A.J. Martinez-Fuentes, J. Cordoba-Chacon, J. Palacios, F. Gracia-Navarro, G. Moreno-Bueno, M.M. Malagon, R.M. Luque, and J.P. Castano. 2011. The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells. Oncogene.
Dvorak, H.F., J.A. Nagy, J.T. Dvorak, and A.M. Dvorak. 1988. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol. 133:95-109.
Epelbaum, J. 1986. Somatostatin in the central nervous system: physiology and pathological modifications. Prog Neurobiol. 27:63-100.
Epelbaum, J., P. Dournaud, M. Fodor, and C. Viollet. 1994. The neurobiology of somatostatin. Crit Rev Neurobiol. 8:25-44.
Fajdic, J., D. Durovic, N. Gotovac, D. Gugic, T. Stastny, and F. Slisuric. 2011. [Ileus caused by metastasis of cutaneous malignant melanoma: case report]. Acta Med Croatica. 65:279-283.
Ferjoux, G., F. Lopez, J.P. Esteve, A. Ferrand, E. Vivier, F. Vely, N. Saint-Laurent, L. Pradayrol, L. Buscail, and C. Susini. 2003. Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation. Mol Biol Cell. 14:3911-3928.
Ferrara, N., K.J. Hillan, and W. Novotny. 2005. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 333:328-335.
Florio, T., M. Morini, V. Villa, S. Arena, A. Corsaro, S. Thellung, M.D. Culler, U. Pfeffer, D.M. Noonan, G. Schettini, and A. Albini. 2003a. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology. 144:1574-1584.
Florio, T., S. Thellung, A. Corsaro, L. Bocca, S. Arena, A. Pattarozzi, V. Villa, A. Massa, F. Diana, D. Schettini, F. Barbieri, J.L. Ravetti, R. Spaziante, M. Giusti, and G. Schettini. 2003b. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin Endocrinol (Oxf). 59:115-128.
Frati, A., M. Antoine, A. Rodenas, J. Gligorov, R. Rouzier, and E. Chereau. 2011. [Somatostatin in breast cancer]. Ann Biol Clin (Paris). 69:385-391.
Frezard, F., and A. Garnier-Suillerot. 1998. Permeability of lipid bilayer to anthracycline derivatives. Role of the bilayer composition and of the temperature. Biochim Biophys Acta. 1389:13-22.
Fussenegger, M., J.E. Bailey, H. Hauser, and P.P. Mueller. 1999. Genetic optimization of recombinant glycoprotein production by mammalian cells. Trends Biotechnol. 17:35-42.
Garcia, M., D. Derocq, G. Freiss, and H. Rochefort. 1992. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc Natl Acad Sci U S A. 89:11538-11542.
Ghielmini, M., S.F. Schmitz, S. Cogliatti, F. Bertoni, U. Waltzer, M.F. Fey, D.C. Betticher, H. Schefer, G. Pichert, R. Stahel, N. Ketterer, M. Bargetzi, and T. Cerny. 2005. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 23:705-711.
Gillies, G. 1997. Somatostatin: the neuroendocrine story. Trends Pharmacol Sci. 18:87-95.
Goormaghtigh, E., and J.M. Ruysschaert. 1984. Anthracycline glycoside-membrane interactions. Biochim Biophys Acta. 779:271-288.
Gopan, O., and Q. Wu. 2012. Evaluation of the Accuracy of a 3D Surface Imaging System for Patient Setup in Head and Neck Cancer Radiotherapy. Int J Radiat Oncol Biol Phys.
Grillo, M., M.J. Bott, N. Khandke, J.P. McGinnis, M. Miranda, M. Meyyappan, E.C. Rosfjord, and S.K. Rabindran. 2006. Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Res Treat. 95:185-194.
Guillermet-Guibert, J., H. Lahlou, S. Pyronnet, C. Bousquet, and C. Susini. 2005. Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: molecular aspects. Best Pract Res Clin Gastroenterol. 19:535-551.
Halmos, G., B. Sun, A.V. Schally, F. Hebert, and A. Nagy. 2000. Human ovarian cancers express somatostatin receptors. J Clin Endocrinol Metab. 85:3509-3512.
He, Y., X.M. Yuan, P. Lei, S. Wu, W. Xing, X.L. Lan, H.F. Zhu, T. Huang, G.B. Wang, R. An, Y.X. Zhang, and G.X. Shen. 2009. The antiproliferative effects of somatostatin receptor subtype 2 in breast cancer cells. Acta Pharmacol Sin. 30:1053-1059.
Hicks, D.G., and C. Whitney-Miller. 2011. HER2 testing in gastric and gastroesophageal junction cancers: a new therapeutic target and diagnostic challenge. Appl Immunohistochem Mol Morphol. 19:506-508.
Hoerr, A.L., F. Gao, J. Hidalgo, D. Tiwari, K.A. Blum, V. Mathews, D.R. Adkins, W. Blum, S. Devine, R. Vij, L.T. Goodnough, J.F. Dipersio, and H.J. Khoury. 2004. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 22:4561-4566.
Hsia, T.C., J.H. Yang, H.J. Lin, C.S. Yu, F.S. Yu, and J.G. Chung. 2004. Paclitaxel inhibits N-acetyltransferase activity and gene expression in human stomach tumor cells (SC-M1). Res Commun Mol Pathol Pharmacol. 115-116:21-38.
Hu, C., C. Yi, Z. Hao, S. Cao, H. Li, X. Shao, J. Zhang, T. Qiao, and D. Fan. 2004. The effect of somatostatin and SSTR3 on proliferation and apoptosis of gastric cancer cells. Cancer Biol Ther. 3:726-730.
Hurley, L.H. 2002. DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer. 2:188-200.
Husain, S.S., I.L. Szabo, R. Pai, B. Soreghan, M.K. Jones, and A.S. Tarnawski. 2001. MAPK (ERK2) kinase--a key target for NSAIDs-induced inhibition of gastric cancer cell proliferation and growth. Life Sci. 69:3045-3054.
Ishiguro, T., N. Takayanagi, M. Ando, T. Yanagisawa, Y. Shimizu, and Y. Sugita. 2011. [Pulmonary tumor thrombotic microangiopathy responding to chemotherapy]. Nihon Kokyuki Gakkai Zasshi. 49:681-687.
Jain, R.K. 1987. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6:559-593.
Jang, S.K., H.G. Krausslich, M.J. Nicklin, G.M. Duke, A.C. Palmenberg, and E. Wimmer. 1988. A segment of the 5' nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. J Virol. 62:2636-2643.
Janson, E.T. 2005. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors. J Endocrinol Invest. 28:137-140.
Johnson, G.L., and R. Lapadat. 2002. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 298:1911-1912.
Jonas, S., M. John, J. Boese-Landgraf, R. Haring, G. Prevost, F. Thomas, S. Rosewicz, E.O. Riecken, B. Wiedenmann, and P. Neuhaus. 1995. Somatostatin receptor subtypes in neuroendocrine tumor cell lines and tumor tissues. Langenbecks Arch Chir. 380:90-95.
Jones, O.M., I. Lindsey, and C. Cunningham. 2011. Laparoscopic colorectal surgery. BMJ. 343:d8029.
Jubin, R., N.E. Vantuno, J.S. Kieft, M.G. Murray, J.A. Doudna, J.Y. Lau, and B.M. Baroudy. 2000. Hepatitis C virus internal ribosome entry site (IRES) stem loop IIId contains a phylogenetically conserved GGG triplet essential for translation and IRES folding. J Virol. 74:10430-10437.
Kabasawa, C., Y. Shimizu, S. Suzuki, M. Masuda, Y. Nagane, K. Utsugisawa, Y. Suzuki, H. Utsumi, K. Fujihara, N. Suzuki, and S. Uchiyama. 2012. Taste disorders in myasthenia gravis: a multicenter cooperative study. Eur J Neurol.
Kaminski, M.S., M. Tuck, J. Estes, A. Kolstad, C.W. Ross, K. Zasadny, D. Regan, P. Kison, S. Fisher, S. Kroll, and R.L. Wahl. 2005. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 352:441-449.
Karantanis, D., M. Allen-Auerbach, and J. Czernin. 2012. Squamous Papilloma of the Oral Cavity and Oropharynx on 18F-FDG PET/CT Imaging. Clin Nucl Med. 37:e98-99.
Karashima, T., R.Z. Cai, and A.V. Schally. 1987. Effects of highly potent octapeptide analogs of somatostatin on growth hormone, insulin and glucagon release. Life Sci. 41:1011-1019.
Karimi Zarchi, M., A.S. Mousavi, and A. Dehghani. 2011. Conservative surgery in cervical cancer: report of two radical abdominal trachelectomies and literature review. Eur J Gynaecol Oncol. 32:710-712.
Kelso, G.F., C.M. Porteous, C.V. Coulter, G. Hughes, W.K. Porteous, E.C. Ledgerwood, R.A. Smith, and M.P. Murphy. 2001. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem. 276:4588-4596.
Keri, G., J. Erchegyi, A. Horvath, I. Mezo, M. Idei, T. Vantus, A. Balogh, Z. Vadasz, G. Bokonyi, J. Seprodi, I. Teplan, O. Csuka, M. Tejeda, D. Gaal, Z. Szegedi, B. Szende, C. Roze, H. Kalthoff, and A. Ullrich. 1996. A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Proc Natl Acad Sci U S A. 93:12513-12518.
Khan, H.A., and A.S. Alhomida. 2011. A review of the logistic role of L-carnitine in the management of radiation toxicity and radiotherapy side effects. J Appl Toxicol. 31:707-713.
Kim, Y.T., N.H. Cho, J.H. Ko, W.I. Yang, J.W. Kim, E.K. Choi, and S.H. Lee. 2000. Expression of cyclin E in placentas with hydropic change and gestational trophoblastic diseases: implications for the malignant transformation of trophoblasts. Cancer. 89:673-679.
Kolb, G.F. 2012. [Myelopoiesis and bone marrow function in elderly tumor patients.]. Z Gerontol Geriatr.
Konstantinopoulos, P.A., M.V. Karamouzis, and A.G. Papavassiliou. 2007. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov. 6:541-555.
Koo, J.S., W. Jung, E. Shin, H.D. Lee, J. Jeong, K.H. Kim, H. Jeong, and S.W. Hong. 2009. Impact of grade, hormone receptor, and HER-2 status in women with breast cancer on response to specific chemotherapeutic agents by in vitro adenosine triphosphate-based chemotherapy response assay. J Korean Med Sci. 24:1150-1157.
Koul, D., R. Shen, S. Bergh, X. Sheng, S. Shishodia, T.A. Lafortune, Y. Lu, J.F. de Groot, G.B. Mills, and W.K. Yung. 2006. Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther. 5:637-644.
Krulich, L., A.P. Dhariwal, and S.M. McCann. 1968. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology. 83:783-790.
Kumar, S., S. Ram, and M. Navazesh. 2011. Salivary gland and associated complications in head and neck cancer therapy. J Calif Dent Assoc. 39:639-647.
Kumar, U. 2011. Cross-talk and modulation of signaling between somatostatin and growth factor receptors. Endocrine. 40:168-180.
Kumar, U., S.I. Grigorakis, H.L. Watt, R. Sasi, L. Snell, P. Watson, and S. Chaudhari. 2005. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1--5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res Treat. 92:175-186.
Lattuada, D., C. Casnici, A. Venuto, and O. Marelli. 2002. The apoptotic effect of somatostatin analogue SMS 201-995 on human lymphocytes. J Neuroimmunol. 133:211-216.
Lee, T.Y., H.C. Wu, Y.L. Tseng, and C.T. Lin. 2004. A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res. 64:8002-8008.
Levin, M., R. Silber, M. Israel, A. Goldfeder, V.K. Khetarpal, and M. Potmesil. 1981. Protein-associated DNA breaks and DNA-protein cross-links caused by DNA nonbinding derivatives of adriamycin in L1210 cells. Cancer Res. 41:1006-1010.
Li, W., and J.R. Bertino. 2002. Fas-mediated signaling enhances sensitivity of human soft tissue sarcoma cells to anticancer drugs by activation of p38 kinase. Mol Cancer Ther. 1:1343-1348.
Li, X., J. Xue, and Y. Lu. 2010. [Current situation and prospect of treatment for radiation-induced lung injury]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 27:937-940.
Liu, H.L., L. Huo, and L. Wang. 2004. Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells. Acta Pharmacol Sin. 25:1380-1386.
Loughrey, H.C., A. Ferraretto, A.M. Cannon, G. Acerbis, F. Sudati, G. Bottiroli, M. Masserini, and M.R. Soria. 1993. Characterisation of biotinylated liposomes for in vivo targeting applications. FEBS Lett. 332:183-188.
Lu, H., S. Zhu, L. Qian, D. Xiang, W. Zhang, A. Nie, J. Gao, M. Wu, B. Lu, Y. Yu, W. Han, and A. Moldenhauer. 2012. Activated expression of the chemokine Mig following chemotherapy contributes to chemotherapy-induced bone marrow suppression and lethal toxicity. Blood.
Luo, X., D. Zhao, L. Guan, Y. Zhou, and H. Shangguan. 2012. [Repair and functional reconstruction of oropharyngeal defects after resection of advanced-stage tonsillar cancer]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 26:50-54.
Macejak, D.G., and P. Sarnow. 1991. Internal initiation of translation mediated by the 5' leader of a cellular mRNA. Nature. 353:90-94.
Majumder, S., and S.T. Jacob. 2011. Emerging role of microRNAs in drug-resistant breast cancer. Gene Expr. 15:141-151.
Marcus, R., K. Imrie, A. Belch, D. Cunningham, E. Flores, J. Catalano, P. Solal-Celigny, F. Offner, J. Walewski, J. Raposo, A. Jack, and P. Smith. 2005. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 105:1417-1423.
Maruyama, K., A. Mori, S. Bhadra, M.T. Subbiah, and L. Huang. 1991. Proteins and peptides bound to long-circulating liposomes. Biochim Biophys Acta. 1070:246-252.
Maturen, K.E., R. Vikram, A.J. Wu, and I.R. Francis. 2012. Renal vein leiomyosarcoma: imaging and clinical features of a renal cell carcinoma mimic. Abdom Imaging.
Mazzucchelli, R., D. Morichetti, A. Santinelli, M. Scarpelli, A.V. Bono, A. Lopez-Beltran, L. Cheng, and R. Montironi. 2011a. Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer. Cell Oncol (Dordr). 34:235-243.
Mazzucchelli, R., D. Morichetti, M. Scarpelli, A.V. Bono, A. Lopez-Beltran, L. Cheng, Z. Kirkali, and R. Montironi. 2011b. Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma. Asian J Androl. 13:242-247.
McLaughlin, P., A.J. Grillo-Lopez, B.K. Link, R. Levy, M.S. Czuczman, M.E. Williams, M.R. Heyman, I. Bence-Bruckler, C.A. White, F. Cabanillas, V. Jain, A.D. Ho, J. Lister, K. Wey, D. Shen, and B.K. Dallaire. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 16:2825-2833.
Mine, B., I. Delpierre, S. Hassid, O. De Witte, and B. Lubicz. 2011. The role of interventional neuroradiology in the management of skull base tumours and related surgical complications. B-ENT. 7 Suppl 17:61-66.
Murphy, W.A., V.A. Lance, S. Moreau, J.P. Moreau, and D.H. Coy. 1987. Inhibition of rat prostate tumor growth by an octapeptide analog of somatostatin. Life Sci. 40:2515-2522.
Nelson, E.M., K.M. Tewey, and L.F. Liu. 1984. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci U S A. 81:1361-1365.
O'Brien, M.E., N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, R. Catane, D.G. Kieback, P. Tomczak, S.P. Ackland, F. Orlandi, L. Mellars, L. Alland, and C. Tendler. 2004. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 15:440-449.
Olson, H.M., D.M. Young, D.J. Prieur, A.F. LeRoy, and R.L. Reagan. 1974. Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits. Am J Pathol. 77:439-454.
Olson, R.D., P.S. Mushlin, D.E. Brenner, S. Fleischer, B.J. Cusack, B.K. Chang, and R.J. Boucek, Jr. 1988. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci U S A. 85:3585-3589.
Omran, S., A.M. Saeed, and J. Simpson. 2012. Symptom distress of Jordanian patients with cancer receiving chemotherapy. Int J Nurs Pract. 18:125-132.
Osada, H., and H. Kakeya. 2004. [Novel angiogenesis inhibitors for molecular target therapy of cancer]. Nihon Rinsho. 62:1257-1263.
Paridaens, R., L. Biganzoli, P. Bruning, J.G. Klijn, T. Gamucci, S. Houston, R. Coleman, J. Schachter, A. Van Vreckem, R. Sylvester, A. Awada, J. Wildiers, and M. Piccart. 2000. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol. 18:724-733.
Park, J.W., K. Hong, D.B. Kirpotin, G. Colbern, R. Shalaby, J. Baselga, Y. Shao, U.B. Nielsen, J.D. Marks, D. Moore, D. Papahadjopoulos, and C.C. Benz. 2002. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res. 8:1172-1181.
Patel, Y.C. 1997. Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest. 20:348-367.
Patel, Y.C. 1999. Somatostatin and its receptor family. Front Neuroendocrinol. 20:157-198.
Pelletier, J., and N. Sonenberg. 1988. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature. 334:320-325.
Perego, P., E. Corna, M. De Cesare, L. Gatti, D. Polizzi, G. Pratesi, R. Supino, and F. Zunino. 2001. Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. Curr Med Chem. 8:31-37.
Peters, J.H., G.R. Gordon, D. Kashiwase, and E.M. Acton. 1981. Tissue distribution of doxorubicin and doxorubicinol in rats receiving multiple doses of doxorubicin. Cancer Chemother Pharmacol. 7:65-69.
Pitino, A., S. Squillaci, C. Spairani, M.F. Cosimi, E. Feyles, D. Ricci, F. Bardari, M. Graziano, F. Morabito, F. Cesarani, M. Garruso, M. Belletti, K. Beierl, and K.M. Murphy. 2011. Primary synovial sarcoma of the kidney. A case report with pathologic appraisal investigation and literature review. Pathologica. 103:271-278.
Plonowski, A., A.V. Schally, A. Nagy, H. Kiaris, F. Hebert, and G. Halmos. 2000. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238. Cancer Res. 60:2996-3001.
Podar, K., and K.C. Anderson. 2005. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood. 105:1383-1395.
Prasher, D.C., V.K. Eckenrode, W.W. Ward, F.G. Prendergast, and M.J. Cormier. 1992. Primary structure of the Aequorea victoria green-fluorescent protein. Gene. 111:229-233.
Prehn, R.T., and J.M. Main. 1957. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 18:769-778.
Radhakrishnan, V., S. Kashyap, N. Pushker, S. Sharma, S. Pathy, B.K. Mohanti, S. Vishnubhatla, S. Ghose, and S. Bakhshi. 2012. Outcome, Pathologic Findings, and Compliance in Orbital Retinoblastoma (International Retinoblastoma Staging System Stage III) Treated with Neoadjuvant Chemotherapy: A Prospective Study. Ophthalmology.
Reichlin, S. 1983. Somatostatin. N Engl J Med. 309:1495-1501.
Reubi, J.C., and B. Waser. 2003. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 30:781-793.
Robbins, R.J. 1996. Somatostatin and cancer. Metabolism. 45:98-100.
Robert, C., and C. Mateus. 2011. [New treatments for metastatic melanoma: a first hope]. Rev Prat. 61:S1-2.
Rowinsky, E.K., G.H. Schwartz, J.A. Gollob, J.A. Thompson, N.J. Vogelzang, R. Figlin, R. Bukowski, N. Haas, P. Lockbaum, Y.P. Li, R. Arends, K.A. Foon, G. Schwab, and J. Dutcher. 2004. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol. 22:3003-3015.
Ruiter, G.A., S.F. Zerp, H. Bartelink, W.J. van Blitterswijk, and M. Verheij. 2003. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs. 14:167-173.
Scherubl, H., M. Bader, U. Fett, B. Hamm, H. Schmidt-Gayk, K. Koppenhagen, F.J. Dop, E.O. Riecken, and B. Wiedenmann. 1993. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. Gastroenterology. 105:1705-1709.
Scott, J.M., A. Khakoo, J.R. Mackey, M.J. Haykowsky, P.S. Douglas, and L.W. Jones. 2011. Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. Circulation. 124:642-650.
Sebolt-Leopold, J.S. 2000. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene. 19:6594-6599.
Segal, N.H., and L.B. Saltz. 2012. Antitumor activity in metastatic disease does not predict efficacy in the adjuvant setting. JAMA. 307:1431-1432.
Segota, S., and D. Tezak. 2006. Spontaneous formation of vesicles. Adv Colloid Interface Sci. 121:51-75.
Serri, O., P. Brazeau, Z. Kachra, and B. Posner. 1992. Octreotide inhibits insulin-like growth factor-I hepatic gene expression in the hypophysectomized rat: evidence for a direct and indirect mechanism of action. Endocrinology. 130:1816-1821.
Shah, N.T., M.G. Kris, W. Pao, L.B. Tyson, B.M. Pizzo, M.H. Heinemann, L. Ben-Porat, D.L. Sachs, R.T. Heelan, and V.A. Miller. 2005. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol. 23:165-174.
Shimomura, O., F.H. Johnson, and Y. Saiga. 1962. Extraction, purification and properties of aequorin, a bioluminescent protein from the luminous hydromedusan, Aequorea. J Cell Comp Physiol. 59:223-239.
Sievers, E.L., R.A. Larson, E.A. Stadtmauer, E. Estey, B. Lowenberg, H. Dombret, C. Karanes, M. Theobald, J.M. Bennett, M.L. Sherman, M.S. Berger, C.B. Eten, M.R. Loken, J.J. van Dongen, I.D. Bernstein, and F.R. Appelbaum. 2001. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 19:3244-3254.
Slamon, D.J., B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga, and L. Norton. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:783-792.
Spelt, L., B. Andersson, J. Nilsson, and R. Andersson. 2012. Prognostic models for outcome following liver resection for colorectal cancer metastases: A systematic review. Eur J Surg Oncol. 38:16-24.
Stockwell, S.R., G. Platt, S.E. Barrie, G. Zoumpoulidou, R.H. Te Poele, G.W. Aherne, S.C. Wilson, P. Sheldrake, E. McDonald, M. Venet, C. Soudy, F. Elustondo, L. Rigoreau, J. Blagg, P. Workman, M.D. Garrett, and S. Mittnacht. 2012. Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signalling. PLoS One. 7:e28568.
Strosberg, J., N. Gardner, and L. Kvols. 2009. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology. 89:471-476.
Susini, C., and L. Buscail. 2006. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 17:1733-1742.
Synowiec, A., G. Wcislo, L. Bodnar, and C. Szczylik. 2012. [Surgical treatment in ovarian cancer prevention in carriers of the BRCA1/BRCA2 mutation]. Ginekol Pol. 83:51-56.
Szekely, B., G. Szentmartoni, J. Kulka, A.M. Szasz, Z. Langmar, and M. Dank. 2011. Primary systemic therapy in breast cancer--an update for gynecologic oncologists. Eur J Gynaecol Oncol. 32:636-641.
Thomann, D., D.R. Rines, P.K. Sorger, and G. Danuser. 2002. Automatic fluorescent tag detection in 3D with super-resolution: application to the analysis of chromosome movement. J Microsc. 208:49-64.
Torchilin, V.P. 2005. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 4:145-160.
Tsai, W.B., I. Aiba, Y. Long, H.K. Lin, L. Feun, N. Savaraj, and M.T. Kuo. 2012. Activation of Ras/PI3K/ERK Pathway Induces c-Myc Stabilization to Upregulate Argininosuccinate Synthetase, Leading to Arginine Deiminase Resistance in Melanoma Cells. Cancer Res.
van der Wal, G.E., A.S. Gouw, J.A. Kamps, H.E. Moorlag, M.L. Bulthuis, G. Molema, and K.P. de Jong. 2012. Angiogenesis in synchronous and metachronous colorectal liver metastases: the liver as a permissive soil. Ann Surg. 255:86-94.
Verslype, C., S. Carton, I. Borbath, T. Delaunoit, P. Demetter, G. Demolin, A. Hendlisz, P. Pattyn, S. Pauwels, M. Peeters, G. Roeyen, P. Van Hootegem, J.L. Van Laethem, and E. Van Cutsem. 2009. The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours. Acta Gastroenterol Belg. 72:54-58.
Virgolini, I., M. Raderer, A. Kurtaran, P. Angelberger, Q. Yang, M. Radosavljevic, M. Leimer, K. Kaserer, S.R. Li, G. Kornek, P. Hubsch, B. Niederle, J. Pidlich, W. Scheithauer, and P. Valent. 1996. 123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nucl Med Biol. 23:685-692.
Vogel, C.L., M.A. Cobleigh, D. Tripathy, J.C. Gutheil, L.N. Harris, L. Fehrenbacher, D.J. Slamon, M. Murphy, W.F. Novotny, M. Burchmore, S. Shak, S.J. Stewart, and M. Press. 2002. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 20:719-726.
Wangberg, B., O. Nilsson, A. Wigander, V. Johansson, E. Forssell-Aronsson, P. Andersson, M. Fjalling, L.E. Tisell, and H. Ahlman. 1997. [Somatostatin receptors. A new way to diagnosis and therapy of neuroendocrine tumors]. Lakartidningen. 94:829-830, 835-828.
Weber, A., A.J. Clark, L.A. Perry, J.W. Honour, and M.O. Savage. 1997. Diminished adrenal androgen secretion in familial glucocorticoid deficiency implicates a significant role for ACTH in the induction of adrenarche. Clin Endocrinol (Oxf). 46:431-437.
Weckbecker, G., I. Lewis, R. Albert, H.A. Schmid, D. Hoyer, and C. Bruns. 2003. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov. 2:999-1017.
Witzig, T.E., L.I. Gordon, F. Cabanillas, M.S. Czuczman, C. Emmanouilides, R. Joyce, B.L. Pohlman, N.L. Bartlett, G.A. Wiseman, N. Padre, A.J. Grillo-Lopez, P. Multani, and C.A. White. 2002. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 20:2453-2463.
Wombacher, R., and V.W. Cornish. 2011. Chemical tags: applications in live cell fluorescence imaging. J Biophotonics. 4:391-402.
Wong, S.C., J.K. Chan, K.C. Lee, and W.L. Hsiao. 2001. Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast. J Pathol. 194:35-42.
Yang, G.H., B.B. Jarvis, Y.J. Chung, and J.J. Pestka. 2000. Apoptosis induction by the satratoxins and other trichothecene mycotoxins: relationship to ERK, p38 MAPK, and SAPK/JNK activation. Toxicol Appl Pharmacol. 164:149-160.
Yeo, H.S., A. Shehzad, and Y.S. Lee. 2012. Prostaglandin E(2) blocks menadione-induced apoptosis through the Ras/Raf/Erk signaling pathway in promonocytic leukemia cell lines. Mol Cells.
Yoshida, K., K. Yamaguchi, N. Okumura, S. Osada, T. Takahashi, Y. Tanaka, K. Tanabe, and T. Suzuki. 2011. The roles of surgical oncologists in the new era: minimally invasive surgery for early gastric cancer and adjuvant surgery for metastatic gastric cancer. Pathobiology. 78:343-352.
Zamora, V., A. Cabanne, R. Salanova, C. Bestani, E. Domenichini, F. Marmissolle, N. Giacomi, J. O'Connor, G. Mendez, and E. Roca. 2010. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis. 42:220-225.
Zunino, F., G. Pratesi, and P. Perego. 2001. Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs. Biochem Pharmacol. 61:933-938.


連結至畢業學校之論文網頁點我開啟連結
註: 此連結為研究生畢業學校所提供,不一定有電子全文可供下載,若連結有誤,請點選上方之〝勘誤回報〞功能,我們會盡快修正,謝謝!
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關論文
 
1. 27. 蕭功秦:〈嚴復與近代新保守主義變革思潮〉,《中國研究月刊》,1996年6月,頁38-44。
2. 27. 蕭功秦:〈嚴復與近代新保守主義變革思潮〉,《中國研究月刊》,1996年6月,頁38-44。
3. 24. 劉子健:〈王安石曾布與北宋晚期官僚的類型〉,《清華學報》,新2卷1期,1960,頁109-129。
4. 24. 劉子健:〈王安石曾布與北宋晚期官僚的類型〉,《清華學報》,新2卷1期,1960,頁109-129。
5. 23. 黃克武:〈嚴復與梁啟超〉,《臺大文史哲學報》,第56期,2002,頁33-68。
6. 23. 黃克武:〈嚴復與梁啟超〉,《臺大文史哲學報》,第56期,2002,頁33-68。
7. 22. 黃克武:〈嚴復的終極追尋:自由主義與文化交融〉,《二十一世紀雙月刊》第67期,2001,頁71-76。
8. 22. 黃克武:〈嚴復的終極追尋:自由主義與文化交融〉,《二十一世紀雙月刊》第67期,2001,頁71-76。
9. 21. 黃克武:〈走向翻譯之路:北洋水師學堂時期的嚴復〉,《中央研究院近代史研究所集刊》,第49期,2005年9月,頁1-40。
10. 21. 黃克武:〈走向翻譯之路:北洋水師學堂時期的嚴復〉,《中央研究院近代史研究所集刊》,第49期,2005年9月,頁1-40。
11. 17. 高大威:〈嚴復的思辨進路及其意義之分析〉,《政大中文學報》,第1期,2004,頁193-227。
12. 17. 高大威:〈嚴復的思辨進路及其意義之分析〉,《政大中文學報》,第1期,2004,頁193-227。
13. 14. 侯美珍:〈明清士人對「評點」的批評〉,《中國文哲研究通訊》,14卷3期,2004年9月,頁223-248。
14. 14. 侯美珍:〈明清士人對「評點」的批評〉,《中國文哲研究通訊》,14卷3期,2004年9月,頁223-248。
15. 13. 周昌龍:〈嚴復自由觀的三層意義〉,《漢學研究》,13卷1期,1995年6月,頁43-59。